Therapeutic Asset Ratings

1,027 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Trastuzumab Emtansine Prostate Carcinoma	OHSU Knight Cancer Institute	P2	B (60)
Trastuzumab Emtansine Recurrent Prostate Carcinoma	OHSU Knight Cancer Institute	P2	B (60)
Trastuzumab Emtansine Refractory Multiple Myeloma	OHSU Knight Cancer Institute	P2	B (60)
Zilovertamab Vedotin Richter Transformation	Merck Sharp & Dohme LLC	P2	B (60)
Mylotarg Myelodysplastic Syndrome	Vor Biopharma	P2/3	B (60)
rc48-adc Capecitabine	The First Affiliated Hospital of Zhengzhou University	P2/3	B (60)
rc48-adc Lung Cancer	Gustave Roussy, Cancer Campus, Grand Paris	P3	B (59)
rc48-adc Pancreas Cancer	Gustave Roussy, Cancer Campus, Grand Paris	P3	B (59)
Trastuzumab Emtansine Breast Neoplasm	Pierre Fabre Pharma GmbH	P3	B (59)
Trastuzumab Emtansine For Breast Cancer	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	P3	B (59)
Ladiratuzumab Vedotin HER2 Positive Breast Carcinoma	Seagen Inc.	P2	B (59)
Polatuzumab Vedotin High Grade B-Cell Lymphoma	Brown University	P2	B (59)
Datopotamab Deruxtecan Breast Cancer	UNC Lineberger Comprehensive Cancer Center	P3	B (58)
Maridebart Cafraglutide Obesity Disorder	Amgen	P3	B (58)
Sacituzumab Tirumotecan Breast Cancer	Shanghai Jiao Tong University School of Medicine	P3	B (58)
Trastuzumab Deruxtecan Ovarian Cancer	Yonsei University	P3	B (58)
Gemtuzumab Ozogamicin Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome	National Cancer Institute (NCI)	P2	B (58)
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide Nasopharyngeal Carcinoma	Sichuan Baili Pharmaceutical Co., Ltd.	P2	B (58)
Polatuzumab Vedotin High Grade B-Cell Lymphoma With MYC And/ Or BCL2 And/Or BCL6 Rearrangement	University of Washington	P2	B (58)
Polatuzumab Vedotin Lymphoma	Beth Israel Deaconess Medical Center	P2	B (58)
Polatuzumab Vedotin Richter Transformation	Christine Ryan	P2	B (58)
Polatuzumab Vedotin T-Cell/Histiocyte Rich Large B Cell Lymphoma	Ruijin Hospital	P2	B (58)
rc48-adc Advanced Colorectal Carcinoma	Fudan University	P2	B (58)
rc48-adc Endometrial Cancer	Seagen, a wholly owned subsidiary of Pfizer	P2	B (58)
rc48-adc Gastric Cancer	BeOne Medicines	P2	B (58)

Showing 176 to 200 of 1,027 assets

PreviousPage 8 of 42Next